Identification of Bioactive Compounds and Potential Mechanisms of Kuntai Capsule in the Treatment of Polycystic Ovary Syndrome by Integrating Network Pharmacology and Bioinformatics

<div>The results of molecular docking between the core targets of the PPI network and their corresponding active ingredients (the four results with the lowest binding energy). (a) Molecular docking results of TP53 and quercetin (binding energy -8.9). (b) Molecular docking results of TP53 and wogonin (binding energy -8.8). (c) Molecular docking results of MAPK1 and quercetin (binding energy -8.7). (d) Molecular docking results of MAPK8 and kaempferol (binding energy -8.7).</div>

Oxidative Medicine and Cellular Longevity

fig7

Figure 7

Figure 7: Identification of Bioactive Compounds and Potential Mechanisms of Kuntai Capsule in the Treatment of Polycystic Ovary Syndrome by Integrating Network Pharmacology and Bioinformatics 

Figure 7 | Identification of Bioactive Compounds and Potential Mechanisms of Kuntai Capsule in the Treatment of Polycystic Ovary Syndrome by Integrating Network Pharmacology and Bioinformatics 